PMID- 30020991
OWN - NLM
STAT- MEDLINE
DCOM- 20190122
LR  - 20230926
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 13
IP  - 7
DP  - 2018
TI  - HLA-A*11:01 is associated with levetiracetam-induced psychiatric adverse events.
PG  - e0200812
LID - 10.1371/journal.pone.0200812 [doi]
LID - e0200812
AB  - Levetiracetam (LEV) is effective for focal and generalized epilepsy and is used 
      worldwide because of its relatively few drug interactions and favorable 
      tolerability. However, some psychiatric adverse events (PAEs) have been reported, 
      resulting in drug withdrawal. The pathophysiology of LEV-induced PAE has not yet 
      been elucidated. In this study, we investigated the relationship between PAEs and 
      human leukocyte antigen (HLA) genes. Eleven epilepsy patients, who developed PAEs 
      after the administration of LEV and spontaneously improved after drug withdrawal, 
      were enrolled retrospectively. Genomic DNA from the peripheral blood was 
      extracted, and four-digit allele genotyping of HLA genes was performed. The 
      genotype frequencies of HLA genes were compared to those of 80 patients in which 
      LEV was well tolerated, as well as to 485 individuals from the general Korean 
      population. The frequency of the HLA-A*1101 allele was significantly higher in 
      the LEV-induced PAEs group compared to both the LEV-tolerant group (p = 0.021, OR 
      4.80, 95% CI 1.30-17.74) and the general Korean population (p = 0.015, OR 4.62, 
      95% CI 1.38-15.45). This study is the first attempt at investigating the 
      relationship between the HLA system and LEV-induced PAE. The results of this 
      study suggest that the HLA-A*1101 allele could be a risk factor for the 
      development of PAEs.
FAU - Yang, Tae-Won
AU  - Yang TW
AUID- ORCID: 0000-0002-8113-2384
AD  - Department of Neurology, Gyeongsang National University Changwon Hospital, 
      Gyeongsang National University College of Medicine, Jinju, Republic of Korea.
FAU - Moon, Jangsup
AU  - Moon J
AD  - Department of Neurology, Laboratory for Neurotherapeutics, Comprehensive Epilepsy 
      Center, Biomedical Research Institute, Seoul National University Hospital, Seoul, 
      Republic of Korea.
AD  - Program in Neuroscience, Seoul National University College of Medicine, Seoul, 
      Republic of Korea.
AD  - Department of Neurosurgery, Seoul National University Hospital, Seoul, Republic 
      of Korea.
FAU - Kim, Tae-Joon
AU  - Kim TJ
AD  - Department of Neurology, Laboratory for Neurotherapeutics, Comprehensive Epilepsy 
      Center, Biomedical Research Institute, Seoul National University Hospital, Seoul, 
      Republic of Korea.
AD  - Program in Neuroscience, Seoul National University College of Medicine, Seoul, 
      Republic of Korea.
FAU - Jun, Jin-Sun
AU  - Jun JS
AD  - Department of Neurology, Kyungpook National University Chilgok Hospital, 
      Kyungpook National University School of Medicine, Daegu, Republic of Korea.
FAU - Lim, Jung-Ah
AU  - Lim JA
AD  - Department of Neurology, Kangnam Sacred Heart Hospital, Hallym University College 
      of Medicine, Seoul, Republic of Korea.
FAU - Lee, Soon-Tae
AU  - Lee ST
AD  - Department of Neurology, Laboratory for Neurotherapeutics, Comprehensive Epilepsy 
      Center, Biomedical Research Institute, Seoul National University Hospital, Seoul, 
      Republic of Korea.
AD  - Program in Neuroscience, Seoul National University College of Medicine, Seoul, 
      Republic of Korea.
FAU - Jung, Keun-Hwa
AU  - Jung KH
AD  - Department of Neurology, Laboratory for Neurotherapeutics, Comprehensive Epilepsy 
      Center, Biomedical Research Institute, Seoul National University Hospital, Seoul, 
      Republic of Korea.
AD  - Program in Neuroscience, Seoul National University College of Medicine, Seoul, 
      Republic of Korea.
FAU - Park, Kyung-Il
AU  - Park KI
AD  - Department of Neurology, Seoul National University Hospital Healthcare System 
      Gangnam Center, Seoul, Republic of Korea.
FAU - Jung, Ki-Young
AU  - Jung KY
AD  - Department of Neurology, Laboratory for Neurotherapeutics, Comprehensive Epilepsy 
      Center, Biomedical Research Institute, Seoul National University Hospital, Seoul, 
      Republic of Korea.
AD  - Program in Neuroscience, Seoul National University College of Medicine, Seoul, 
      Republic of Korea.
FAU - Chu, Kon
AU  - Chu K
AD  - Department of Neurology, Laboratory for Neurotherapeutics, Comprehensive Epilepsy 
      Center, Biomedical Research Institute, Seoul National University Hospital, Seoul, 
      Republic of Korea.
AD  - Program in Neuroscience, Seoul National University College of Medicine, Seoul, 
      Republic of Korea.
FAU - Lee, Sang Kun
AU  - Lee SK
AD  - Department of Neurology, Laboratory for Neurotherapeutics, Comprehensive Epilepsy 
      Center, Biomedical Research Institute, Seoul National University Hospital, Seoul, 
      Republic of Korea.
AD  - Program in Neuroscience, Seoul National University College of Medicine, Seoul, 
      Republic of Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180718
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (HLA-A Antigens)
RN  - 44YRR34555 (Levetiracetam)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Alleles
MH  - Epilepsy/drug therapy/genetics
MH  - Female
MH  - Genotype
MH  - HLA-A Antigens/*genetics
MH  - Humans
MH  - Levetiracetam/*adverse effects
MH  - Male
MH  - Middle Aged
MH  - Republic of Korea
MH  - Retrospective Studies
PMC - PMC6051654
COIS- The authors have declared that no competing interests exist.
EDAT- 2018/07/19 06:00
MHDA- 2019/01/23 06:00
PMCR- 2018/07/18
CRDT- 2018/07/19 06:00
PHST- 2018/04/02 00:00 [received]
PHST- 2018/07/03 00:00 [accepted]
PHST- 2018/07/19 06:00 [entrez]
PHST- 2018/07/19 06:00 [pubmed]
PHST- 2019/01/23 06:00 [medline]
PHST- 2018/07/18 00:00 [pmc-release]
AID - PONE-D-18-09902 [pii]
AID - 10.1371/journal.pone.0200812 [doi]
PST - epublish
SO  - PLoS One. 2018 Jul 18;13(7):e0200812. doi: 10.1371/journal.pone.0200812. 
      eCollection 2018.